Marty Makary’s resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.
Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3
After a 12-month period that saw the Belgian biotech consider a spinout, swap out CEOs, and enter a three-way acquisition agreement involving Ouro Medicines, Galapagos now...
A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their...
After devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving. But analysts don’t expect...
BOSTON – When Kiran Musunuru, MD, PhD, walked to the microphone to deliver remarks on behalf of the team that won the American Society of Gene...
Post-Hoc: Why FDA Commissioner Marty Makary was ousted
Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping...
BOSTON – The annual American Society of Cell and Gene Therapy (ASGCT) conference got underway in Boston this week with a guest appearance by one of...
Several hospitals have received federal grand jury subpoenas regarding the provision of gender-affirming care to minors, according to a statement from NYU Langone, a step that...